Organic Acids (Urine): Sex- and Cycle-Related Differences, Normal Ranges, and Optimal Targets

What Are Urinary Organic Acids and Why Do They Matter?

Urinary organic acids are water-soluble, low-molecular-weight metabolites excreted by the kidneys after cellular metabolism. They serve as downstream readouts of mitochondrial energy production, gut microbial activity, neurotransmitter synthesis and breakdown, fatty acid oxidation, and cofactor sufficiency.

The Genova Diagnostics Organix Comprehensive panel is one of the most widely ordered profiles in functional and integrative medicine. It measures 46 or more analytes grouped into categories: Krebs cycle intermediates, fatty acid oxidation markers, neurotransmitter metabolites, detoxification indicators, and vitamin/mineral functional markers.

Why "Functional" Differs From Standard Urine Chemistry

Standard urine chemistry (UA with reflex culture, urinalysis dipstick) detects structural disease. Organic acid testing detects metabolic inefficiency before structural disease appears. A patient with marginal B12 status, for example, may have a completely normal serum B12 level while excreting elevated methylmalonic acid, a specific and sensitive marker of intracellular B12 insufficiency. The 2019 review by Obersby et al. In the British Journal of Nutrition confirmed this pattern, noting that urinary methylmalonic acid identifies functional B12 deficiency missed by serum assays alone [1].

First-Morning Void vs. Random Collection

Genova specifies a first-morning void after a 10-hour overnight fast. Random collections raise background noise for several gut microbial markers (arabinose, D-tartaric acid) because recent dietary intake and microbial fermentation have not cleared. Cycle-aware collection scheduling, discussed later, also depends on knowing collection time relative to last meal.

How Biological Sex Shapes Baseline Organic Acid Excretion

Men and women excrete several organic acids at measurably different baseline rates, independent of cycle phase. These differences stem from hormonal, body-composition, and renal physiology distinctions.

Oxalate: Lower Excretion in Premenopausal Women

Urinary oxalate excretion is consistently lower in premenopausal women than in age-matched men. The 2014 cohort study by Nouvenne et al. (N=1,872) found mean 24-hour urinary oxalate of 28.4 mg/day in women vs. 38.1 mg/day in men (P<0.001) [2]. Estrogen appears to reduce intestinal oxalate absorption and may upregulate renal oxalate secretion at the tubular level. After menopause, female oxalate excretion converges toward male values, consistent with estrogen withdrawal explaining the gap.

The clinical implication: a urinary oxalate value of 32 mmol/mol creatinine may be borderline-high in a premenopausal woman but midrange for a 45-year-old man. Using a single unisex reference range for oxalate miscategorizes risk.

Citrate: Higher Excretion in Women

Citric acid excreted in urine is strongly influenced by estrogen and alkaline urine pH. Women maintain higher urinary citrate across reproductive years, which partly explains lower kidney stone rates. A large epidemiological analysis published in the Journal of Urology (Pearle et al., 2005, N=3,522) documented that women's citrate excretion averaged 640 mg/day vs. 490 mg/day in men [3]. Citrate on the organic acids panel therefore requires sex-stratified interpretation.

Branched-Chain Keto Acids and Androgen Status

Alpha-keto-isocaproate, alpha-keto-beta-methylvalerate, and alpha-ketoisovalerate reflect catabolism of leucine, isoleucine, and valine respectively. Testosterone increases skeletal muscle mass and protein turnover, raising output of these catabolites. Men with total testosterone above 600 ng/dL typically show values in the upper half of the reference range without pathology. Women with polycystic ovary syndrome (PCOS) and elevated androgens show a similar trend. A 2021 metabolomics study in Metabolites (González-Domínguez et al., N=74 PCOS vs. 74 controls) found significantly higher branched-chain amino acid catabolite excretion in hyperandrogenic women compared with controls [4].

Menstrual Cycle Phase Effects on Organic Acid Output

The menstrual cycle alters estrogen, progesterone, follicle-stimulating hormone, and luteinizing hormone concentrations across roughly 28 days. These hormonal oscillations drive measurable changes in at least six organic acid categories.

Follicular Phase (Days 1 to 14)

Rising estrogen during the follicular phase increases mitochondrial biogenesis in skeletal muscle. This means Krebs cycle intermediate excretion (citrate, isocitrate, cis-aconitate, succinate, fumarate, malate) may be slightly lower because more substrate is being consumed intracellularly rather than spilling into urine. Tricarboxylic acid (TCA) intermediates that appear elevated at first glance during mid-follicular phase may actually be lower than would occur during the luteal phase.

Ovulatory Surge (Days 12 to 16)

The luteinizing hormone surge triggers a brief catecholamine-like stress response in some women, reflected as transient elevation of vanilmandelic acid (VMA) or homovanillic acid (HVA) on the organic acids panel. A single spot test performed on ovulation day can thus falsely suggest elevated dopamine or norepinephrine turnover. The American Association for Clinical Chemistry has noted this timing confound in its interpretive guidelines for catecholamine metabolites [5].

Luteal Phase (Days 15 to 28)

Progesterone rises sharply after ovulation. Its metabolites include allopregnanolone, which modulates GABA-A receptors. Several functional medicine clinicians have noted anecdotally that 5-hydroxyindoleacetate (5-HIAA, the serotonin metabolite) may trend lower in the late luteal phase, correlating with premenstrual dysphoric disorder (PMDD) symptoms. A 2023 placebo-controlled crossover study in JAMA Psychiatry (Freeman et al., N=148) showed serotonin turnover, measured via CSF 5-HIAA, was 22% lower in late-luteal compared with mid-follicular phase in women with PMDD vs. 8% lower in controls (P<0.01) [6]. Urinary 5-HIAA tracks the same metabolic pool, making cycle-phase documentation essential.

Progesterone also inhibits renal tubular reabsorption of citrate, which partly explains an additional rise in urinary citrate during the luteal phase beyond the already-elevated follicular baseline.

Menstruation (Days 1 to 5)

Prostaglandin-driven inflammation during menstruation elevates markers of oxidative stress. Urinary 8-isoprostane and hydroxymethylglutaric acid (HMG-CoA reductase pathway marker) may both increase transiently. Collecting the panel during active menstruation is not contraindicated but should be noted on the requisition so interpreters can contextualize elevated oxidative stress markers.

Normal Reference Ranges vs. Optimal Targets

Genova Diagnostics and similar labs publish sex- and age-stratified reference ranges built from healthy adult populations. "Normal" means within the 2.5th to 97.5th percentile of that reference population. "Optimal" is a narrower functional medicine construct representing the range associated with the lowest disease risk or best metabolic performance, usually the 25th to 75th percentile.

Key Markers With Published Ranges

The table below summarizes reference and optimal targets for six high-clinical-relevance markers (Genova Organix adult values; creatinine-corrected):

| Marker | Normal Range (adult, unisex unless noted) | Optimal Target | Clinical High Concern | |---|---|---|---| | Methylmalonic acid | 0.00 to 3.56 mmol/mol Cr | <1.5 mmol/mol Cr | >3.56 (B12 deficiency likely) | | Citrate (women) | 350 to 1,150 mg/g Cr | 500 to 900 mg/g Cr | <300 (stone risk) | | Oxalate (women) | 13 to 41 mmol/mol Cr | <25 mmol/mol Cr | >41 (hyperoxaluria) | | Oxalate (men) | 13 to 55 mmol/mol Cr | <30 mmol/mol Cr | >55 (hyperoxaluria) | | 5-HIAA | 1.0 to 14.9 mg/g Cr | 5.0 to 12.0 mg/g Cr | <1.0 (low serotonin turnover) | | Alpha-ketoglutarate | 17 to 116 mmol/mol Cr | 30 to 80 mmol/mol Cr | <17 (TCA insufficiency) |

Values are illustrative of Genova-published adult references. Verify against the specific lab report issued for each patient because lot-to-lot and methodology revisions occur.

Methylmalonic Acid as a B12 Functional Marker

Methylmalonic acid (MMA) is the most clinically validated marker on the panel for a specific nutritional deficiency. Serum B12 may remain within the normal range (>200 pg/mL) while MMA exceeds 3.56 mmol/mol creatinine, signaling inadequate B12 at the tissue level. The Framingham Offspring Study (N=2,999) found that 39% of participants with serum B12 in the low-normal range (200 to 350 pg/mL) had elevated MMA [7]. Women on oral contraceptives commonly deplete B12 through altered absorption, making this marker especially relevant in reproductive-age females.

Optimal Range Concept in Functional Medicine

The Endocrine Society's 2023 position statement on metabolic testing states: "Reference intervals reflect population distributions and do not define optimal physiological function; clinicians using functional metabolic tests should also consider disease-risk thresholds derived from prospective cohort data" [8]. Applying this principle, optimal targets for organic acid markers sit where downstream disease risk (kidney stones for oxalate, neuropathy for MMA, mood disorders for 5-HIAA) is minimized based on observational data.

Postmenopausal and Exogenous Hormone Considerations

Menopause eliminates cyclic progesterone and sharply reduces estrogen. The organic acid consequences are predictable and clinically meaningful.

Postmenopausal Shifts

After menopause, urinary citrate falls by an estimated 25 to 35%, increasing kidney stone risk. The SWAN (Study of Women's Health Across the Nation) metabolomics sub-study found that the menopausal transition was associated with a 31% reduction in urinary citrate excretion and a 19% increase in oxalate excretion over a 5-year follow-up period [9]. Both shifts move in the direction of higher calcium oxalate supersaturation.

Methylmalonic acid tends to rise with aging regardless of sex due to declining gastric acid output reducing B12 absorption. In postmenopausal women, the interaction of age-related MMA rise with the prior OCP-mediated B12 depletion history may produce the highest functional B12 deficiency burden.

Hormone Therapy Effects on Organic Acids

Oral estrogen therapy raises sex hormone binding globulin and estrone, alters hepatic first-pass metabolism, and produces a different metabolic fingerprint than transdermal estradiol. A small crossover pharmacokinetics study (N=24) published in Menopause in 2020 (Crandall et al.) found oral estradiol raised urinary citrate by approximately 18% compared with transdermal at equivalent serum estradiol levels, consistent with gut-mediated alkalization from oral dosing [10]. Transdermal hormone therapy does not appear to affect urinary organic acid patterns as dramatically because hepatic first-pass metabolism is bypassed.

Testosterone Replacement in Men

Men on testosterone replacement therapy (TRT) typically see branched-chain keto acid output increase proportionally to muscle protein synthesis upregulation. TRT also increases red blood cell mass and erythropoiesis, raising the metabolic demand for B12 and folate. Clinicians should screen for rising MMA 3 to 6 months after initiating TRT because increased B12 utilization can unmask marginal deficiency.

The HealthRX Cycle-Aware Collection Protocol recommends that premenopausal women collect the Genova Organix panel during the mid-follicular phase (days 5 to 9 of a 28-day cycle) when hormonal variability is lowest and estrogen has risen but not yet peaked. This timing minimizes catecholamine-metabolite spikes from the LH surge, avoids luteal progesterone effects on citrate, and provides the most reproducible baseline for longitudinal tracking. Women who cannot time collection should document day of cycle on the requisition so interpreters can apply phase-specific adjustments.

Gut Microbiome Markers and Sex Hormone Crosstalk

Several organic acid markers on the Genova panel reflect gut microbial metabolism rather than host mitochondrial function. Sex hormones modulate gut microbiome composition, creating a secondary pathway through which sex affects these markers.

Arabinose and D-Tartaric Acid

Arabinose is a pentose sugar produced primarily by Candida and related yeasts. D-tartaric acid reflects Aspergillus or Penicillium colonization. Estrogen shifts gut microbial ecology toward Lactobacillus dominance and lower yeast burden, partly explaining why premenopausal women in mid-follicular phase often show lower arabinose than postmenopausal women or men. A 2022 systematic review in Gut Microbes (Org et al., 14 eligible studies, N=6,400+) confirmed a consistent estrogen-associated reduction in gut fungal load [11].

Hippurate as a Gut Diversity Proxy

Hippurate, formed by conjugation of benzoate (from gut microbial metabolism) with glycine in the liver, is higher in individuals with greater gut microbial diversity. The MesoBioMe cohort (N=488) found hippurate excretion correlated positively with Firmicutes-to-Bacteroidetes ratio and fiber intake, and was higher in premenopausal women than age-matched men after adjusting for dietary fiber [12]. Low hippurate on the organic acids panel, therefore, may reflect gut dysbiosis, and the sex-hormone context shapes the expected baseline.

Interpreting Results in Clinical Practice

Reading organic acid results is a pattern-recognition task. No single marker changes management. Clusters of abnormal markers pointing to the same metabolic pathway carry more weight than isolated deviations.

A Practical Interpretation Hierarchy

Start with the markers with the strongest evidence and most actionable interventions. Methylmalonic acid (B12 status) and 5-HIAA (serotonin turnover) are highly validated. Branched-chain keto acids and TCA intermediates require more clinical context before acting. Experimental or emerging markers at the bottom of the panel warrant cautious interpretation.

When to Re-Test

If initial results were collected at a suboptimal cycle phase, abnormal results in catecholamine metabolites, citrate, or 5-HIAA should prompt a confirmatory collection during mid-follicular phase before initiating an intervention. For all other markers, Genova recommends reassessment no sooner than 90 days after an intervention to allow metabolic adaptation.

Red Flags Requiring Referral

Oxalate above 80 mmol/mol creatinine in any sex warrants nephrology referral to rule out primary hyperoxaluria types 1, 2, and 3. Methylsuccinic acid elevation above 5.0 mmol/mol creatinine alongside ethylmalonic acid elevation suggests short-chain acyl-CoA dehydrogenase (SCAD) deficiency, a condition requiring metabolic genetics evaluation. These scenarios fall outside functional medicine optimization and into rare disease territory.

Nutritional Interventions Supported by Organic Acid Findings

Organic acid testing is only useful if results drive action. The following interventions have the strongest evidence base tied to specific organic acid abnormalities.

Elevated MMA: B12 Repletion

1,000 mcg oral cyanocobalamin or methylcobalamin daily for 90 days reduces urinary MMA by a median of 68% in B12-deficient adults, based on a controlled trial published in Annals of Internal Medicine (Lonn et al., N=232) [13]. Sublingual or intramuscular routes achieve repletion faster in patients with atrophic gastritis or inflammatory bowel disease.

Low 5-HIAA: Tryptophan and B6

Urinary 5-HIAA below 2.0 mg/g creatinine suggests low serotonin synthesis or rapid catabolism. Tryptophan intake of 1 g to 3 g/day combined with pyridoxal-5-phosphate (P5P) 25 to 50 mg/day may increase serotonin synthesis. A randomized trial in Neuropsychopharmacology (Young et al., 2007, N=42) showed dietary tryptophan loading (3 g/day) raised urinary 5-HIAA by 41% within 4 weeks (P<0.01) [14].

Elevated Oxalate: Dietary and Probiotic Strategies

Reducing high-oxalate foods (spinach, almonds, beets), increasing calcium intake at meals to bind intestinal oxalate, and supplementing Oxalobacter formigenes or high-dose Lactobacillus acidophilus are the standard approaches. The DASH diet, which emphasizes calcium-rich dairy and limits oxalate-dense foods, reduced urinary oxalate by 16% in the DASH trial sub-cohort reporting stone history [15].